Marlborough, MA – October 17, 2025 – Boston Scientific Corporation announced that it has entered into a definitive agreement to acquire Nalu Medical, Inc., a California-based developer of innovative neurostimulation and pain management systems. The acquisition aims to strengthen Boston Scientific’s presence in neuromodulation and chronic pain therapy, integrating Nalu’s miniaturized neurostimulation technology into its growing medical device portfolio. This strategic move reflects Boston Scientific’s continued focus on expanding next-generation therapeutic solutions for patients with chronic pain and peripheral nerve conditions.
Science Significance
The acquisition highlights the scientific and technological synergy between Boston Scientific and Nalu Medical. Nalu’s proprietary miniaturized implantable pulse generator (IPG) technology delivers non-opioid, neurostimulation-based pain relief using advanced algorithms and wireless communication. This innovation addresses the limitations of conventional neurostimulators by offering longer battery life, reduced invasiveness, and enhanced patient comfort. By incorporating Nalu’s research-driven platform, Boston Scientific will accelerate the development of data-enabled neuromodulation therapies, advancing scientific progress in neural interface engineering and digital health integration.
Regulatory Significance
From a regulatory standpoint, the transaction underscores the importance of FDA-cleared medical devices in expanding safe and effective alternatives for pain management. Nalu’s system, already approved for chronic pain of the trunk and limbs, aligns with FDA’s ongoing efforts to promote non-pharmacologic interventions for chronic pain amid the opioid reduction initiative. The acquisition further enhances Boston Scientific’s compliance framework under cGMP and ISO 13485 standards, ensuring consistent regulatory alignment across its neuromodulation product pipeline.
Business Significance
Advertisement
This deal represents a strategic acquisition within Boston Scientific’s long-term plan to diversify and strengthen its pain management portfolio. The company already holds a minority stake in Nalu Medical and has now opted for a full acquisition to consolidate its intellectual property and expand its market leadership in neuromodulation. Financially, the agreement includes an upfront payment of approximately $1.2 billion, with up to $400 million in potential milestone-based payments. This investment is expected to enhance Boston Scientific’s earnings growth and expand its revenue base in the MedTech pain therapy market, projected to exceed $6 billion globally by 2030.
Patients’ Significance
For patients, the acquisition promises greater access to minimally invasive, drug-free pain therapies. Nalu’s miniaturized neurostimulation implant provides an effective and convenient alternative to opioid treatments, reducing the risks of dependency while maintaining sustained pain relief. Patients benefit from remote programmability and mobile app connectivity, which enable personalized therapy management. The combined expertise of Boston Scientific and Nalu Medical will thus deliver more efficient, patient-friendly pain treatment solutions, significantly improving quality of life for chronic pain sufferers.
Policy Significance
The acquisition aligns with U.S. healthcare policy initiatives aimed at expanding non-opioid pain management solutions and promoting innovation in digital health technologies. It supports national efforts to integrate AI, wireless communication, and minimally invasive techniques into medical devices. Additionally, it reinforces the FDA’s regulatory modernization goals, encouraging collaboration between large-scale MedTech firms and early-stage innovators to drive accessible and compliant medical technologies for public health improvement.
The acquisition of Nalu Medical by Boston Scientific represents a transformative milestone in MedTech innovation, combining advanced neurostimulation science with robust commercial capability. This merger will strengthen Boston Scientific’s commitment to addressing the global burden of chronic pain while adhering to the highest regulatory and ethical standards. As the company continues to integrate Nalu’s pioneering neurostimulation technologies, it sets a new benchmark in digital, patient-centric, and sustainable healthcare innovation, reaffirming its leadership in the future of neuromodulation and pain therapy.
Source: Boston Scientific Corporation press release
